1. Generics Bulletin
  2. >>Business
  3. >>Deals

Medac Will Market Fresenius Kabi’s Adalimumab In Germany

Collaboration On Idacio Will Begin From The Start Of June

 
• By Dave Wallace

Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.

Germany_Handshake
Fresenius Kabi and Medac have struck a German deal • Source: Shutterstock

Fresenius Kabi says it has struck a deal with Medac that will see Fresenius’ Idacio (adalimumab) biosimilar for treating autoimmune illnesses such as arthritis and psoriasis marketed in Germany by Medac from the start of June.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.